RxDoctor Payments Data

Adam Nomberg, MD

Ophthalmology · Plainview, NYNPI 1851393847

Payments from drug & device makers

$2,282in general payments, 2019–2025

Across 77 payments — averaging $29.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$898
  • AbbVie$772
  • Tarsus Pharmaceuticals, Inc.$148
  • Aerie Pharmaceuticals, Inc.$119
  • Bausch & Lomb Americas Inc.$117
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$98
  • plus $130 from 3 others

What the payments were for

  • Food & beverage$2,26499%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,282 in reported general payments places this provider in the 60th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$166,669
Medicare patients
518
Services billed
1,909

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost174$118,226
RhopressaNetarsudil Mesylate58$31,332
Alphagan PBrimonidine Tartrate37$23,931
RestasisCyclosporine14$23,310
VyzultaLatanoprostene Bunod32$16,966
SimbrinzaBrinzolamide/Brimonidine Tart49$16,033
RocklatanNetarsudil Mesylat/Latanoprost14$11,743
Lotemax SmLoteprednol Etabonate44$10,712
Travoprost34$10,652
Brinzolamide36$8,179
BesivanceBesifloxacin Hcl34$7,332
CombiganBrimonidine Tartrate/Timolol11$6,429
ProlensaBromfenac Sodium18$6,022
Dorzolamide-TimololDorzolamide/Timolol/Pf17$4,985
Loteprednol Etabonate22$2,757

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Alphagan P, Restasis, Combigan$772$171,895236 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$119$43,07572 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Besivance, Prolensa, Loteprednol Etabonate$98$26,823118 claims
Bausch & Lomb Americas Inc.Vyzulta$117$16,96632 claims
AlconSimbrinza$898$16,03349 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Plainview

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →